Viking Global Boosts Mallinckrodt Position ~ market folly

Monday, August 31, 2015

Viking Global Boosts Mallinckrodt Position

Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding its position in Mallinckrodt (MNK).  Per the filing, Viking now owns 4.9% of the company with over 5.72 million shares.

This is up slightly from the 5.41 million shares they owned at the end of the second quarter.  The filing was made due to activity on August 21st.

We've also highlighted some of Viking Global's short positions here.

Per Google Finance, Mallinckrodt is "a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Company’s Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Company’s Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product."

blog comments powered by Disqus